Ozempic manufacturer to cut 9,000 roles

Novo Nordisk, the Denmark-based manufacturer of Ozempic, said Sept. 10 it plans to reduce approximately 9,000 of its 78,400 global roles. 

The drugmaker said in a news release the workforce reductions will save 8 billion Danish Krone, or about $1 billion, by the end of 2026. Around 5,000 of the layoffs will occur in Denmark. 

Novo Nordisk said the move aims to “simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company’s growth opportunities in diabetes and obesity.”

The post Ozempic manufacturer to cut 9,000 roles appeared first on Becker’s Hospital Review | Healthcare News & Analysis.